Despite an already strong run, ADMA Biologics, Inc. (NASDAQ:ADMA) shares have been powering on, with a gain of 53% in the last thirty days. The annual gain comes to 136% following the latest surge, making investors sit up and take notice.
Even after such a large jump in price, ADMA Biologics may still be sending buy signals at present with its price-to-sales (or "P/S") ratio of 7.9x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 12.2x and even P/S higher than 66x aren't out of the ordinary. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.
NasdaqGM:ADMA Price to Sales Ratio vs Industry May 22nd 2024
How Has ADMA Biologics Performed Recently?
Recent times haven't been great for ADMA Biologics as its revenue has been rising slower than most other companies. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on ADMA Biologics.
What Are Revenue Growth Metrics Telling Us About The Low P/S?
There's an inherent assumption that a company should underperform the industry for P/S ratios like ADMA Biologics' to be considered reasonable.
Taking a look back first, we see that the company grew revenue by an impressive 56% last year. Spectacularly, three year revenue growth has ballooned by several orders of magnitude, thanks in part to the last 12 months of revenue growth. Accordingly, shareholders would have been over the moon with those medium-term rates of revenue growth.
Turning to the outlook, the next three years should generate growth of 20% per year as estimated by the four analysts watching the company. That's shaping up to be materially lower than the 211% per annum growth forecast for the broader industry.
With this information, we can see why ADMA Biologics is trading at a P/S lower than the industry. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.
The Bottom Line On ADMA Biologics' P/S
ADMA Biologics' stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
We've established that ADMA Biologics maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.
We don't want to rain on the parade too much, but we did also find 1 warning sign for ADMA Biologics that you need to be mindful of.
If these risks are making you reconsider your opinion on ADMA Biologics, explore our interactive list of high quality stocks to get an idea of what else is out there.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
尽管ADMA Biologics, Inc.(纳斯达克股票代码:ADMA)的股价已经表现强劲,但在过去的三十天里,其股价仍然上涨了53%。在最近的飙升之后,年涨幅达到136%,这使投资者坐下来注意了。
即使在价格大幅上涨之后,ADMA Biologics目前仍可能以7.9倍的市销率(或 “市销率”)发出买入信号,因为美国生物技术行业几乎有一半公司的市销率超过12.2倍,甚至市盈率高于66倍也并非不寻常。但是,市销率低可能是有原因的,需要进一步调查以确定其是否合理。
纳斯达克通用汽车公司:ADMA 与行业的股价销售比率 2024 年 5 月 22 日
ADMA 生物制剂最近的表现如何?
最近对ADMA Biologics来说并不是一件好事,因为其收入的增长速度比大多数其他公司都要慢。看来许多人预计平淡无奇的收入表现将持续下去,这抑制了市销率的增长。如果是这样的话,那么现有股东可能很难对股价的未来走向感到兴奋。
如果你想了解分析师对未来的预测,你应该查看我们关于ADMA Biologics的免费报告。
收入增长指标告诉我们低市销率有哪些?
人们固有的假设是,如果像ADMA Biologics这样的市销率被认为是合理的,公司的表现应该低于该行业。
首先回顾一下,我们发现该公司去年的收入增长了令人印象深刻的56%。引人注目的是,三年的收入增长激增了几个数量级,这在一定程度上要归功于过去12个月的收入增长。因此,有了这些中期收入增长率,股东们就会大吃一惊。
展望来看,根据关注该公司的四位分析师的估计,未来三年将实现每年20%的增长。这将大大低于整个行业预期的211%的年增长率。
有了这些信息,我们可以了解为何ADMA Biologics的市销售率低于该行业。显然,许多股东不愿坚持下去,而该公司可能正在考虑不那么繁荣的未来。
ADMA Biologics 市销率的底线
ADMA Biologics的股价最近飙升,但其市销率仍然不高。通常,我们倾向于限制使用市销率来确定市场对公司整体健康状况的看法。
我们已经确定,ADMA Biologics维持了较低的市销率,原因是其预期的增长低于整个行业,正如预期的那样。目前,股东们正在接受低市销率,因为他们承认未来的收入可能不会带来任何惊喜。在这种情况下,很难看到股价在不久的将来强劲上涨。
我们不想在游行队伍中下太多雨,但我们也找到了一个需要注意的ADMA Biologics警告标志。
如果这些风险让你重新考虑你对ADMA Biologics的看法,请浏览我们的高质量股票互动清单,了解还有什么。
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。